Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Urinary Bladder Neoplasms 3Glioblastoma 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-invasive Urothelial Cancer of the Bladder 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Craniopharyngioma 1Carcinoma 1Brain Neoplasms 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × Transurethral Resection of Bladder × Clear all
NCT06805305 2026-04-23

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Diakonos Oncology Corporation

Phase 2 Recruiting
180 enrolled
CNS

Glioblastoma

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡